Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

38 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-27

Study Completion Date

2021-12-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a VLP SARS-CoV-2 vaccine study of a vaccine developed in Turkey and manufactured according to Good Manufacturing Practices (GMP) requirements. Preclinical toxicology studies on experimental animals are to be concluded. The purpose of this Phase I study is to examine the safety, tolerability, and immunogenicity of the protective VLP vaccine against SARS-CoV-2, which will be administered by a double-blind, randomized method, in two different doses (low dose and high dose).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of a Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine

NCT04962893

Covid19

COMPLETED PHASE2

Safety and Immunogenicity of the Inactivated Koçak-19 Inaktif Adjuvanlı COVID-19 Vaccine Compared to Placebo

NCT04838080

COVID-19 Vaccine

UNKNOWN PHASE1

Comparative Evaluation of Covid-19 Vaccines Response

NCT04895007

COVID-19 Vaccines

UNKNOWN

Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults

NCT04866069

Covid19

TERMINATED PHASE1

Evaluation of the Efficacy, Safety and Immunogenicity of Inactivated COVID 19 Vaccine(TURKOVAC) in Healthy Population of 18 and 64 Years of Age (Both Inclusive):a Randomized, Double-blind, Phase IIb Clinical Trial

NCT05035238

Covid19

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This phase I study is designed as double-blinded, randomised, placebo controlled, three-armed study composed of two different dose arms of protective VLP vaccine (harboring M, N, E, and hexapro modified S proteins of SARS-CoV-2 virus) against SARS-CoV-2 in dose escalations (first low dose group, followed by high dose group) and placebo arm. Each dose of vaccine will be defined as a cohort in itself, with vaccine administration to 12 participants and placebo administration to 6 participants. After completion of low-dose group, decision of switch to high-dose will be taken by the Independent Data Monitoring Committee and study will continue accordingly.

The study will be completed in 12 months.

All injections will be done subcutaneously.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

DOUBLE

Participants Investigators

Double-blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low-Dose Group (Group A)

12 participants will receive 10 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)

Group Type EXPERIMENTAL

SARS-CoV-2 VLP Vaccine

Intervention Type BIOLOGICAL

VLP adjuvanted vaccine

High-Dose Group (Group B)

12 participants will receive 40 µg VLP vaccine (adjuvanted with alum and CpGODN-K3)

Group Type EXPERIMENTAL

SARS-CoV-2 VLP Vaccine

Intervention Type BIOLOGICAL

VLP adjuvanted vaccine

Placebo Group

12 participants will receive 1 ml of 0.9% sodium chloride (NaCl)

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

0.9% NaCl

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SARS-CoV-2 VLP Vaccine

VLP adjuvanted vaccine

Intervention Type BIOLOGICAL

Placebo

0.9% NaCl

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

To be eligible for the study, each participant must satisfy all the following criteria:

1. Healthy participants between 18-59 years of age,
2. Sign an informed consent document,
3. Negative immunoglobulin G (IgG) and immunoglobulin M (IgM) antibody for COVID-19,
4. Negative quantitative polymerase chain reaction (qPCR) SARS-CoV-2 results of nasopharyngeal/sputum samples,
5. Able to comply with the study protocol during the study period,
6. Negative tests for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV),
7. Body temperature \<37.2 C,
8. Body mass index 18-35 kg/m2,
9. Normal laboratory levels of whole blood count, alanine transaminase (ALT), aspartate transaminase (AST), total bilirubin, urea, creatinine, and fasting blood glucose,
10. Good general health (no known disease in the history and physical examination within 14 days prior to the enrolment),
11. Female participants who are not pregnant or who will be able to have appropriate contraception methods within 30 days prior to vaccine injection and within 6 months after vaccination,
12. Male participants who will be able to have appropriate contraception methods for 6 months after vaccination,

Exclusion Criteria

Participants with any of the following criteria will be excluded:

1. History of seizure, encephalopathy or psychosis,
2. History of allergic reactions to any known vaccine or to any component of the study vaccine,
3. Pregnant, breastfeeding or positive pregnancy test or planning to conceive within 6 months,
4. Active infection signs or body temperature \>37.2 C,
5. History of SARS-CoV-2 infection,
6. Severe cardiovascular disorders (arrhythmia, conduction disorders, history of myocardial infarction, uncontrolled hypertension),
7. Severe chronic disorders (asthma, diabetes mellitus, thyroid disorders…etc),
8. Congenital or acquired angioedema,
9. Diagnosis of immunodeficiency,
10. Diagnosis of bleeding diathesis,
11. Use of immunosuppressive treatment, anti-allergic treatment, cytotoxic treatment, inhaler corticosteroids (allergic rhinitis or topical steroid ointments are excluded),
12. Those who received blood and blood product transfusions in the last 6 months,
13. Those on any vaccine program or experimental medication within 1 month prior to the study,
14. History of any live vaccine administration within 1 month prior to the study,
15. History of any inactive vaccine administration within 1 month prior to the study,
16. Use of active tuberculosis treatment,
17. According to the investigator's evaluation, those who have any condition (medical, psychological, social, etc.) that may impair the patient's compliance with the study will be excluded from the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

59 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes